Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  paclitaxel
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 1286 for your search:
Start Over
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML18527, NCT00121836
Combination Chemotherapy in Treating Older Patients With Solid Tumour,
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 75 and over
Sponsor: Other
Protocol IDs: CDR0000593133, GERCOR-OLD, EudraCT-2007004103-36, GERCOR-OLD07-SA07-1, NCT00664911
Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 97-02-12, NCT00686322
A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML22780, 2009-014279-37, NCT01094184
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25288, NCT01301729
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001KDE37, EudraCT 2010-022273-34, 2010-022273-34, NCT01317615
Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MITO-16 - MANGO-OV2, 2012-003043-29, NCT01706120
Phase II/III Randomized Study of a New Paclitaxel Formulation Given by 3-Hour vs 96-Hour Infusion in Women with Refractory Metastatic Breast Cancer (Summary Last Modified 11/95)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: any age
Sponsor: Other
Protocol IDs: MAOP-1195, NCI-V95-0749
Combination Chemotherapy in Treating Men With Germ Cell Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 16 to 50
Sponsor: Other
Protocol IDs: EORTC-30983, NCT00003643
Phase II/III Randomized Trial of DOX vs TAX vs DOX/TAX/G-CSF in Patients with Metastatic Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: E-1193, NCCTG-923252, SWOG-9332, E-10292, E1193
Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA139-384, NCT00337532
Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 40 to 75
Sponsor: Other
Protocol IDs: Hamamatsu 18-66, NCT00752115
Paclitaxel and Carboplatin With or Without BMS-275291 in Treating Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR18, CAN-NCIC-BR18, BMS-CA161-003, CDR0000068153, NCT00006229
Paclitaxel and Carboplatin With or Without Cediranib Maleate in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: BR24, CAN-NCIC-BR24, ZENECA-CAN-NCIC-BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B, CDR0000450850, NCT00245154
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02947, E4599, U10CA021115, CDR0000068744, ECOG-4599, CALGB-E4599, NCT00021060
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000657121, SINGAPORE-NCC0901, NCC0901, NCT00997906
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL/09/105, Funder reference (academic), Funder reference (industry), 2009-017171-13, NCT01196741
Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 66, 2011-000553-23, NCT01426880
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CBKM120F2202, 2011-005932-24, NCT01572727
Phase III Randomized Study of Paclitaxel Administered as a 3-Hour Infusion at Three Different Doses in Women with Recurrent Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CLB-9342, CALGB-9342
Start Over